Synthesis and Molecular Docking Studies of 5-Trifluoromethoxy-2-Indolinones as Cholinesterase Dual Inhibitors

References

• DeTure MA , DicksonDW. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener.14, 32 (2019).
   PubMed Web of Science ®Google Scholar
• Fan L , MaoC, HuXet al. New insights into the pathogenesis of Alzheimer’s disease. Front. Neurol.10, 1312 (2020).
   PubMed Web of Science ®Google Scholar
• Du X , WangX, GengM. Alzheimer’s disease hypothesis and related therapies. Transl. Neurodegener.7, 2 (2018).
   PubMed Web of Science ®Google Scholar
• Liston DR , NielsenJA, VillalobosAet al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur. J. Pharmacol.486(1), 9–17 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar V , SahaA, RoyK. In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer’s disease. Comput. Biol. Chem.88, 107355 (2020).
   PubMed Web of Science ®Google Scholar
• Greig NH , UtsukiT, IngramDKet al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc. Natl Acad. Sci. USA102(47), 17213–17218 (2005).
   PubMed Web of Science ®Google Scholar
• Greig NH , LahiriDK, SambamurtiK. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy. Int. Psychogeriatr.14(S1), 77–91 (2002).
   PubMedGoogle Scholar
• Sharma K . Cholinesterase inhibitors as Alzheimer’s therapeutics (review). Mol. Med. Rep.20(2), 1479–1487 (2019).
   PubMed Web of Science ®Google Scholar
• Marucci G , BuccioniM, BenDD, LambertucciC, VolpiniR, AmentaF. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacology190, 108352 (2021).
   PubMed Web of Science ®Google Scholar
• Hampel H , MesulamMM, CuelloAC. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain141(7), 1917–1933 (2018).
   PubMed Web of Science ®Google Scholar
• Crismon ML . Tacrine: first drug approved for Alzheimer’s disease. Ann. Pharmacother.28(6), 744–751 (1994).
   PubMed Web of Science ®Google Scholar
• Shintani EY , UchidaKM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am. J. Health Syst. Pharm.54(24), 2805–2810 (1997).
   PubMed Web of Science ®Google Scholar
• Nguyen K , HoffmanH, ChakkamparambilB, GrossbergGT. Evaluation of rivastigmine in Alzheimer’s disease. Neurodegener. Dis. Manag.11(1), 35–48 (2021).
   PubMed Web of Science ®Google Scholar
• Razay G , WilcockGK. Galantamine in Alzheimer’s disease. Expert Rev. Neurother.8, 9–17 (2008).
   PubMedGoogle Scholar
• Medvedev AE , BuneevaOA, KopylovATet al. The effects of endogenous non-peptide molecule isatin and hydrogen peroxide on proteomic profiling of rat brain amyloid-β binding proteins: relevance to Alzheimer’s disease? Int. J. Mol. Sci. 16(1), 476–495 (2014).
   PubMed Web of Science ®Google Scholar
• Medvedev A , BuneevaO, GnedenkoO, ErshovP, IvanovA. Isatin, an endogenous nonpeptide biofactor: a review of its molecular targets, mechanisms of actions, and their biomedical implications. Biofactors44(2), 95–108 (2018).
   PubMed Web of Science ®Google Scholar
• Ershov PV , MezentsevYV, YablokovEOet al. Effect of bioregulator isatin on protein–protein interactions involving isatin-binding proteins. Russ. J. Bioorg. Chem.44(2), 176–182 (2018).
   Web of Science ®Google Scholar
• Riazimontazer E , SadeghpourH, NadriHet al. Design, synthesis and biological activity of novel tacrine–isatin Schiff base hybrid derivatives. Bioorg. Chem.89, 103006 (2019).
   PubMed Web of Science ®Google Scholar
• Ozgun DO , YamaliC, GulHIet al. Inhibitory effects of isatin Mannich bases on carbonic anhydrases, acetylcholinesterase, and butyrylcholinesterase. J. Enzyme Inhib. Med. Chem.31(6), 1498–1501 (2016).
   PubMed Web of Science ®Google Scholar
• Zhou L , ZhuY, JiangY, ZhaoX, GuoD. Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer’s disease. Bioorg. Med. Chem. Lett.27(17), 4180–4184 (2017).
   PubMed Web of Science ®Google Scholar
• Akrami H , MirjaliliBF, KhoobiMet al. Indolinone-based acetylcholinesterase inhibitors: synthesis, biological activity and molecular modeling. Eur. J. Med. Chem.84, 375–381 (2014).
   PubMed Web of Science ®Google Scholar
• Reiland KM , EckroatTJ. Selective butyrylcholinesterase inhibition by isatin dimers and 3-indolyl-3-hydroxy-2-oxindole dimers. Bioorg. Med. Chem. Lett.77, 129037 (2022).
   PubMed Web of Science ®Google Scholar
• Totobenazara J , BacalhauP, JuanAASet al. Design, synthesis and bioassays of 3-substituted-3-hydroxyoxindoles for cholinesterase inhibition. ChemistrySelect1(13), 3580–3588 (2016).
   Web of Science ®Google Scholar
• Bacalhau P , FernandesL, MartinsMRet al. In silico, NMR and pharmacological evaluation of an hydroxyoxindole cholinesterase inhibitor. Bioorg. Med. Chem.27(2), 354–363 (2019).
   PubMed Web of Science ®Google Scholar
• Koçyiğit ÜM , DoğanM, MuğluHet al. Determination of biological studies and molecular docking calculations of isatin–thiosemicarbazone hybrid compounds. J. Mol. Struct.1264, 133249 (2022).
   Web of Science ®Google Scholar
• Demir-Yazıcı K , ApaydinÇB, Soylu-EterÖ, ÖzsoyN, KaralıN. Synthesis, molecular modeling and cholinesterase inhibitory effects of 2-indolinone-based hydrazinecarbothioamides. Future Med. Chem.13(24), 2133–2151 (2021).
   PubMed Web of Science ®Google Scholar
• Apaydın ÇB , Soylu-EterÖ, Eraslan-ElmaP, ÖzsoyN, KaralıN. Synthesis and molecular modeling studies of 1-benzyl-2-indolinones as selective AChE inhibitors. Future Med. Chem.14(23), 1705–1723 (2022).
   PubMed Web of Science ®Google Scholar
• Huang H , ChenQ, KuXet al. A series of α-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIα catalytic activity. J. Med. Chem.53(8), 3048–3064 (2010).
   PubMed Web of Science ®Google Scholar
• Serra S , MoineauxL, VancraeynestCet al. Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties. Eur. J. Med. Chem.82, 96–105 (2014).
   PubMed Web of Science ®Google Scholar
• Vine KL , LockeJM, RansonM, PyneSG, BremnerJB. An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J. Med. Chem.50(21), 5109–5117 (2007).
   PubMed Web of Science ®Google Scholar
• Karalı N , GöktaşF, Cihan-ÜstündağG, EraslanElma P. N-[(Aminosulfonyl)phenyl]-2-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazinecarbothioamide derivatives for treating cancer and immunological disorders. WO 2017099695 A1 (2017).
   Google Scholar
• Soylu-Eter Ö , SevinçliZŞ, ErsoyBet al. 5-Fluoro/(trifluoromethoxy)-2-indolinone derivatives with anti-interleukin-1 activity. Arch. Pharm.356(12), e2300217 (2023).
   PubMed Web of Science ®Google Scholar
• Soylu Eter Ö , AtioğluZ, AkkurtM, ErsanlıCC, KaralıN. Molecular and crystal structure of 1-methyl 5-trifluoromethoxy-1H-indole-2,3-dione 3-[4-(4-methoxyphenyl)thiosemicarbazone]. Istanbul J. Pharm.51(1), 59–66 (2021).
   Web of Science ®Google Scholar
• Gürsoy A , KaraliN, BüyüktimkinS, DemirayakS, EkinciAC, OzerH. Some 3-hydrazono-2-indolinones and N-Mannich bases as potential anticonvulsants. Farmaco51(6), 437–442 (1996).
   PubMedGoogle Scholar
• Karali N , GürsoyA. Synthesis and anticonvulsant activity of some new thiosemicarbazone and 4-thiazolidone derivatives bearing an isatin moiety. Farmaco49(12), 819–822 (1994).
   PubMedGoogle Scholar
• Ellman GL , CourtneyKD, AndresV, FeatherstoneRM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol.7(2), 88–95 (1961).
   PubMed Web of Science ®Google Scholar
• Wichur T , PasiekaA, GodyńJet al. Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau. Eur. J. Med. Chem.225, 113783 (2021).
   PubMed Web of Science ®Google Scholar
• Schrödinger-Small-Molecule Drug Discovery Suite Release 2018-3: Maestro. Schrödinger, LLC, New York, NY, USA (2018).
   Google Scholar
• Cheung J , RudolphMJ, BurshteynFet al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem.55(22), 10282–10286 (2012).
   PubMed Web of Science ®Google Scholar
• Nachon F , CarlettiE, RoncoCet al. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer’s drugs targeting acetyl- and butyryl-cholinesterase. Biochem. J.453(3), 393–399 (2013).
   PubMedGoogle Scholar
• Rosenberry TL , BrazzolottoX, MacdonaldIRet al. Comparison of the binding of reversible inhibitors to human butyrylcholinesterase and acetylcholinesterase: a crystallographic, kinetic and calorimetric study. Molecules22(12), 2098 (2017).
   PubMed Web of Science ®Google Scholar
• Lipinski CA , LombardoF, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.23(1–3), 3–25 (1997).
   Web of Science ®Google Scholar
• van Breemen , Li. Caco-2 cell permeability assays to measure drug absorption. Expert Opin. Drug Metab. Toxicol.1(2), 175–185 (2005).
   PubMedGoogle Scholar
• Irvine et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci.88(1), 28–33 (1999).
   PubMed Web of Science ®Google Scholar